Tuberculosis and Respiratory Diseases

The Korean Academy of Tuberculosis and Respiratory Diseases (대한결핵및호흡기학회)
권호 표지
DOI QR코드

DOI QR Code

Tumor Immunology and Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer

  • Jung, Chi Young (Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Daegu Catholic University School of Medicine) ;
  • Antonia, Scott J. (Department of Thoracic Oncology, H. Lee Moffitt Cancer Center and Research Institute)
  • Received : 2017.11.01
  • Accepted : 2017.11.26
  • Published : 2018.01.31
Download PDF
⟨ Previous Next ⟩

Abstract

Lung cancer is one of the most commonly diagnosed cancers and the leading cause of cancer-related deaths worldwide. Although progress in the treatment of advanced non-small cell lung cancer (NSCLC) has been made over the past decade, the 5-year survival rate in patients with lung cancer remains only 10%-20%. Obviously, new therapeutic options are required for patients with advanced NSCLC and unmet medical needs. Cancer immunotherapy is an evolving treatment modality that uses a patient's own immune systems to fight cancer. Theoretically, cancer immunotherapy can result in long-term cancer remission and may not cause the same side effects as chemotherapy and radiation. Immunooncology has become an important focus of basic research as well as clinical trials for the treatment of NSCLC. Immune checkpoint inhibitors are the most promising approach for cancer immunotherapy and they have become the standard of care for patients with advanced NSCLC. This review summarizes basic tumor immunology and the relevant clinical data on immunotherapeutic approaches, especially immune checkpoint inhibitors in NSCLC.

Keywords

References

  1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136:E359-86. https://doi.org/10.1002/ijc.29210
  2. Korea Central Cancer Registry. Annual report of cancer statistics in Korea in 2013 [Internet]. Goyang: National Cancer Information Center; 2016 [cited 2016 Jun 20]. Available from: http://www.cancer.go.kr/.
  3. Korean Statistical Information Service. Statistics Korea [Internet]. Daejeon: Statistics Korea; 2016 [cited 2016 Jun 20]. Available from: http://kosis.kr/.
  4. Reck M, Heigener DF, Mok T, Soria JC, Rabe KF. Management of non-small-cell lung cancer: recent developments. Lancet 2013;382:709-19. https://doi.org/10.1016/S0140-6736(13)61502-0
  5. National Comprehensive Cancer Network. NCCN Clinical practice guidelines in oncology: non-small cell lung cancer. Version 9. 2017 [Internet]. Fort Washington: National Comprehensive Cancer Network; 2017 [cited 2017 Sep 28]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf.
  6. Midha A, Dearden S, McCormack R. EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII). Am J Cancer Res 2015;5:2892-911.
  7. Park JY, Jang SH. Epidemiology of lung cancer in Korea: recent trends. Tuberc Respir Dis 2016;79:58-69.
  8. Allemani C, Weir HK, Carreira H, Harewood R, Spika D, Wang XS, et al. Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet 2015;385:977-1010. https://doi.org/10.1016/S0140-6736(14)62038-9
  9. Shepherd FA, Douillard JY, Blumenschein GR Jr. Immunotherapy for non-small cell lung cancer: novel approaches to improve patient outcome. J Thorac Oncol 2011;6:1763-73. https://doi.org/10.1097/JTO.0b013e31822e28fc
  10. Thomas A, Hassan R. Immunotherapies for non-small-cell lung cancer and mesothelioma. Lancet Oncol 2012;13:e301-10. https://doi.org/10.1016/S1470-2045(12)70126-2
  11. Reck M. What future opportunities may immuno-oncology provide for improving the treatment of patients with lung cancer? Ann Oncol 2012;23 Suppl 8:viii28-34.
  12. Brahmer JR. Harnessing the immune system for the treatment of non-small-cell lung cancer. J Clin Oncol 2013;31:1021-8. https://doi.org/10.1200/JCO.2012.45.8703
  13. Massarelli E, Papadimitrakopoulou V, Welsh J, Tang C, Tsao AS. Immunotherapy in lung cancer. Transl Lung Cancer Res 2014;3:53-63.
  14. Anagnostou VK, Brahmer JR. Cancer immunotherapy: a future paradigm shift in the treatment of non-small cell lung cancer. Clin Cancer Res 2015;21:976-84. https://doi.org/10.1158/1078-0432.CCR-14-1187
  15. Carbone DP, Gandara DR, Antonia SJ, Zielinski C, Paz-Ares L. Non-small-cell lung cancer: role of the immune system and potential for immunotherapy. J Thorac Oncol 2015;10:974-84. https://doi.org/10.1097/JTO.0000000000000551
  16. Abbas AK, Lichtman AH, Pillai S. Cellular and molecular immunology. 9th ed. Philadelphia: Saunders/Elsevier; 2018.
  17. Liu Y, Zeng G. Cancer and innate immune system interactions: translational potentials for cancer immunotherapy. J Immunother 2012;35:299-308. https://doi.org/10.1097/CJI.0b013e3182518e83
  18. Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ. Natural innate and adaptive immunity to cancer. Annu Rev Immunol 2011;29:235-71. https://doi.org/10.1146/annurev-immunol-031210-101324
  19. Finn OJ. Immuno-oncology: understanding the function and dysfunction of the immune system in cancer. Ann Oncol 2012;23 Suppl 8:viii6-9.
  20. Eggermont AM. Can immuno-oncology offer a truly pantumour approach to therapy? Ann Oncol 2012;23 Suppl 8:viii53-7.
  21. Burnet M. Cancer: a biological approach. I. The processes of control. Br Med J 1957;1:779-86. https://doi.org/10.1136/bmj.1.5022.779
  22. Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001;410:1107-11. https://doi.org/10.1038/35074122
  23. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002;3:991-8. https://doi.org/10.1038/ni1102-991
  24. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011;331:1565-70. https://doi.org/10.1126/science.1203486
  25. Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity 2013;39:1-10. https://doi.org/10.1016/j.immuni.2013.07.012
  26. Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature 2011;480:480-9. https://doi.org/10.1038/nature10673
  27. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12:252-64. https://doi.org/10.1038/nrc3239
  28. Butt AQ, Mills KH. Immunosuppressive networks and checkpoints controlling antitumor immunity and their blockade in the development of cancer immunotherapeutics and vaccines. Oncogene 2014;33:4623-31. https://doi.org/10.1038/onc.2013.432
  29. Ruffini E, Asioli S, Filosso PL, Lyberis P, Bruna MC, Macri L, et al. Clinical significance of tumor-infiltrating lymphocytes in lung neoplasms. Ann Thorac Surg 2009;87:365-71.
  30. Hiraoka K, Miyamoto M, Cho Y, Suzuoki M, Oshikiri T, Nakakubo Y, et al. Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-smallcell lung carcinoma. Br J Cancer 2006;94:275-80. https://doi.org/10.1038/sj.bjc.6602934
  31. Petersen RP, Campa MJ, Sperlazza J, Conlon D, Joshi MB, Harpole DH Jr, et al. Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients. Cancer 2006;107:2866-72. https://doi.org/10.1002/cncr.22282
  32. Drake CG, Lipson EJ, Brahmer JR. Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer. Nat Rev Clin Oncol 2014;11:24-37. https://doi.org/10.1038/nrclinonc.2013.208
  33. Vansteenkiste J, Zielinski M, Linder A, Dahabreh J, Gonzalez EE, Malinowski W, et al. Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results. J Clin Oncol 2013;31:2396-403. https://doi.org/10.1200/JCO.2012.43.7103
  34. Vansteenkiste JF, Cho BC, Vanakesa T, De Pas T, Zielinski M, Kim MS, et al. Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2016;17:822-35. https://doi.org/10.1016/S1470-2045(16)00099-1
  35. Butts C, Socinski MA, Mitchell PL, Thatcher N, Havel L, Krzakowski M, et al. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial. Lancet Oncol 2014;15:59-68. https://doi.org/10.1016/S1470-2045(13)70510-2
  36. Wu YL, Park K, Soo RA, Sun Y, Tyroller K, Wages D, et al. INSPIRE: a phase III study of the BLP25 liposome vaccine (LBLP25) in Asian patients with unresectable stage III nonsmall cell lung cancer. BMC Cancer 2011;11:430. https://doi.org/10.1186/1471-2407-11-430
  37. Quoix E, Lena H, Losonczy G, Forget F, Chouaid C, Papai Z, et al. TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebocontrolled, phase 2b/3 trial. Lancet Oncol 2016;17:212-23. https://doi.org/10.1016/S1470-2045(15)00483-0
  38. Rodriguez PC, Popa X, Martinez O, Mendoza S, Santiesteban E, Crespo T, et al. A phase III clinical trial of the epidermal growth factor vaccine CIMAvax-EGF as switch maintenance therapy in advanced non-small cell lung cancer patients. Clin Cancer Res 2016;22:3782-90. https://doi.org/10.1158/1078-0432.CCR-15-0855
  39. Sasada T, Komatsu N, Suekane S, Yamada A, Noguchi M, Itoh K. Overcoming the hurdles of randomised clinical trials of therapeutic cancer vaccines. Eur J Cancer 2010;46:1514-9. https://doi.org/10.1016/j.ejca.2010.03.013
  40. Mellstedt H, Vansteenkiste J, Thatcher N. Vaccines for the treatment of non-small cell lung cancer: investigational approaches and clinical experience. Lung Cancer 2011;73:11-7. https://doi.org/10.1016/j.lungcan.2011.02.023
  41. Cuppens K, Vansteenkiste J. Vaccination therapy for nonsmall-cell lung cancer. Curr Opin Oncol 2014;26:165-70. https://doi.org/10.1097/CCO.0000000000000052
  42. Makkouk A, Weiner GJ. Cancer immunotherapy and breaking immune tolerance: new approaches to an old challenge. Cancer Res 2015;75:5-10.
  43. Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 2015;373:123-35.
  44. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 2015;373:1627-39. https://doi.org/10.1056/NEJMoa1507643
  45. Carbone DP, Reck M, Paz-Ares L, Creelan B, Horn L, Steins M, et al. First-Line Nivolumab in stage IV or recurrent non-smallcell lung cancer. N Engl J Med 2017;376:2415-26. https://doi.org/10.1056/NEJMoa1613493
  46. Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 2015;372:2018-28. https://doi.org/10.1056/NEJMoa1501824
  47. Herbst RS, Baas P, Kim DW, Felip E, Perez-Gracia JL, Han JY, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 2016;387:1540-50. https://doi.org/10.1016/S0140-6736(15)01281-7
  48. Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fulop A, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 2016;375:1823-33. https://doi.org/10.1056/NEJMoa1606774
  49. Brahmer JR, Rodriguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fulop A, et al. Progression after the next line of therapy (PFS2) and updated OS among patients (pts) with advanced NSCLC and PD-L1 tumor proportion score (TPS) ${\geq}$50% enrolled in KEYNOTE-024. J Clin Oncol 2017;35(15 Suppl): 9000.
  50. Fehrenbacher L, Spira A, Ballinger M, Kowanetz M, Vansteenkiste J, Mazieres J, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet 2016;387:1837-46. https://doi.org/10.1016/S0140-6736(16)00587-0
  51. Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 2017;389:255-65. https://doi.org/10.1016/S0140-6736(16)32517-X
  52. Garassino M, Vansteenkiste J, Kim JH, Lena H, Mazieres J, Powderly J, et al. Durvalumab in ${\geq}$3rd-line locally advanced or metastatic, EGFR/ALK wild-type NSCLC: results from the phase 2 ATLANTIC study. J Thorac Oncol 2017;12(Suppl):S10-1. https://doi.org/10.1016/j.jtho.2016.11.012
  53. Peters S, Gettinger S, Johnson ML, Janne PA, Garassino MC, Christoph D, et al. Phase II trial of atezolizumab as first-line or subsequent therapy for patients with programmed deathligand 1-selected advanced non-small-cell lung cancer (BIRCH). J Clin Oncol 2017;35:2781-9. https://doi.org/10.1200/JCO.2016.71.9476
  54. Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Durvalumab after chemoradiotherapy in stage III nonsmall-cell lung cancer. N Engl J Med 2017;377:1919-29. https://doi.org/10.1056/NEJMoa1709937
  55. Lynch TJ, Bondarenko I, Luft A, Serwatowski P, Barlesi F, Chacko R, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV nonsmall-cell lung cancer: results from a randomized, doubleblind, multicenter phase II study. J Clin Oncol 2012;30:2046-54. https://doi.org/10.1200/JCO.2011.38.4032
  56. Govindan R, Szczesna A, Ahn MJ, Schneider CP, Gonzalez Mella PF, Barlesi F, et al. Phase III trial of ipilimumab combined with paclitaxel and carboplatin in advanced squamous non-small-cell lung cancer. J Clin Oncol 2017;35:3449-57. https://doi.org/10.1200/JCO.2016.71.7629
  57. Champiat S, Ileana E, Giaccone G, Besse B, Mountzios G, Eggermont A, et al. Incorporating immune-checkpoint inhibitors into systemic therapy of NSCLC. J Thorac Oncol 2014;9:144-53. https://doi.org/10.1097/JTO.0000000000000074
  58. Antonia SJ, Larkin J, Ascierto PA. Immuno-oncology combinations: a review of clinical experience and future prospects. Clin Cancer Res 2014;20:6258-68. https://doi.org/10.1158/1078-0432.CCR-14-1457
  59. Langer CJ, Gadgeel SM, Borghaei H, Papadimitrakopoulou VA, Patnaik A, Powell SF, et al. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous nonsmall-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol 2016;17:1497-508. https://doi.org/10.1016/S1470-2045(16)30498-3
  60. Borghaei H, Langer CJ, Gadgeel S, Papadimitrakopoulou VA, Patnaik A, Powell SF, et al. Updated results from KEYNOTE-021 cohort G: a randomized, phase 2 study of pemetrexed and carboplatin (PC) with or without pembrolizumab (pembro) as first-line therapy for advanced nonsquamous NSCLC. Ann Oncol 2017;28(Suppl_5):636-7.
  61. Rizvi NA, Hellmann MD, Brahmer JR, Juergens RA, Borghaei H, Gettinger S, et al. Nivolumab in combination with platinum-based doublet chemotherapy for first-line treatment of advanced non-small-cell lung cancer. J Clin Oncol 2016;34:2969-79. https://doi.org/10.1200/JCO.2016.66.9861
  62. Hellmann MD, Rizvi NA, Goldman JW, Gettinger SN, Borghaei H, Brahmer JR, et al. Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. Lancet Oncol 2017;18:31-41.
  63. Antonia S, Goldberg SB, Balmanoukian A, Chaft JE, Sanborn RE, Gupta A, et al. Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study. Lancet Oncol 2016;17:299-308. https://doi.org/10.1016/S1470-2045(15)00544-6
  64. Remon J, Chaput N, Planchard D. Predictive biomarkers for programmed death-1/programmed death ligand immune checkpoint inhibitors in nonsmall cell lung cancer. Curr Opin Oncol 2016;28:122-9.
  65. Gridelli C, Ardizzoni A, Barberis M, Cappuzzo F, Casaluce F, Danesi R, et al. Predictive biomarkers of immunotherapy for non-small cell lung cancer: results from an Experts Panel Meeting of the Italian Association of Thoracic Oncology. Transl Lung Cancer Res 2017;6:373-86.
  66. Chae YK, Pan A, Davis AA, Raparia K, Mohindra NA, Matsangou M, et al. Biomarkers for PD-1/PD-L1 blockade therapy in non-small-cell lung cancer: is PD-L1 expression a good marker for patient selection? Clin Lung Cancer 2016;17:350-61. https://doi.org/10.1016/j.cllc.2016.03.011
  67. Gibney GT, Weiner LM, Atkins MB. Predictive biomarkers for checkpoint inhibitor-based immunotherapy. Lancet Oncol 2016;17:e542-51. https://doi.org/10.1016/S1470-2045(16)30406-5
  68. Sacher AG, Gandhi L. Biomarkers for the clinical use of PD-1/PD-L1 inhibitors in non-small-cell lung cancer: a review. JAMA Oncol 2016;2:1217-22. https://doi.org/10.1001/jamaoncol.2016.0639
  69. Hirsch FR, McElhinny A, Stanforth D, Ranger-Moore J, Jansson M, Kulangara K, et al. PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the blueprint PD-L1 IHC assay comparison project. J Thorac Oncol 2017;12:208-22. https://doi.org/10.1016/j.jtho.2016.11.2228
  70. Rimm DL, Han G, Taube JM, Yi ES, Bridge JA, Flieder DB, et al. A prospective, multi-institutional, pathologist-based assessment of 4 immunohistochemistry assays for PD-L1 expression in non-small cell lung cancer. JAMA Oncol 2017;3:1051-8. https://doi.org/10.1001/jamaoncol.2017.0013
  71. Buttner R, Gosney JR, Skov BG, Adam J, Motoi N, Bloom KJ, et al. Programmed death-ligand 1 immunohistochemistry testing: a review of analytical assays and clinical implementation in non-small-cell lung cancer. J Clin Oncol 2017;35:3867-76.
  72. Scheerens H, Malong A, Bassett K, Boyd Z, Gupta V, Harris J, et al. Current status of companion and complementary diagnostics: strategic considerations for development and launch. Clin Transl Sci 2017;10:84-92. https://doi.org/10.1111/cts.12455
  73. Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 2013;499:214-8. https://doi.org/10.1038/nature12213
  74. Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, et al. Cancer immunology: mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015;348:124-8. https://doi.org/10.1126/science.aaa1348

Cited by

  1. Current status and future directions of cancer immunotherapy vol.9, pp.10, 2018, https://doi.org/10.7150/jca.24577
  2. Hypoxia-induced cancer stemness acquisition is associated with CXCR4 activation by its aberrant promoter demethylation vol.19, pp.None, 2019, https://doi.org/10.1186/s12885-019-5360-7
  3. Endoplasmic reticulum stress enhances the antigen-specific T cell immune responses and therapeutic antitumor effects generated by therapeutic HPV vaccines vol.26, pp.1, 2018, https://doi.org/10.1186/s12929-019-0536-7
  4. Molecular and Immune Characteristics for Lung Adenocarcinoma Patients With ERLIN2 Overexpression vol.11, pp.None, 2018, https://doi.org/10.3389/fimmu.2020.568440
  5. Current Status of Immunotherapy for Lung Cancer and Future Perspectives vol.83, pp.1, 2020, https://doi.org/10.4046/trd.2019.0039
  6. Recent Trends of Lung Cancer in Korea vol.84, pp.2, 2021, https://doi.org/10.4046/trd.2020.0134
  7. Hsp70 in Liquid Biopsies-A Tumor-Specific Biomarker for Detection and Response Monitoring in Cancer vol.13, pp.15, 2021, https://doi.org/10.3390/cancers13153706